Hormone Replacement Therapy and Risk of New-Onset Atrial Fibrillation after Myocardial Infarction - A Nationwide Cohort Study

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Bretler, Ditte Marie ^a   Hansen, Peter Riis ^a   Lindhardsen, Jesper ^a   Ahlehoff, Ole ^a   Andersson, Charlotte ^a   Jensen, Thomas Bo ^a   Raunsø, Jakob ^a,c   Torp Pedersen, Christian ^a,b   Gislason, Gunnar Hilmar ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONSET AGE; RETROSPECTIVE STUDY; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; DENMARK; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; RISK FACTORS;

EID: 84871300951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051580     Document Type: Article

References (50)

1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, et al. (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27: 949-953.
2. Andersson P, Londahl M, Abdon NJ, Terent A, (2012) The prevalence of atrial fibrillation in a geographically well-defined population in Northern Sweden: implications for anticoagulation prophylaxis. J Intern Med 272(2): 170-6.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, et al. (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98: 946-952.
4. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, et al. (2001) New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103: 2365-2370.
5. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, et al. (2011) Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA 305: 2080-2087.
6. Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, et al. (2011) Atrial fibrillation and death after myocardial infarction: a community study. Circulation 123: 2094-2100.
7. Lokkegaard E, Lidegaard O, Moller LN, Agger C, Andreasen AH, et al. (2007) Hormone replacement therapy in Denmark, 1995-2004. Acta Obstet Gynecol Scand 86: 1342-1351.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613.
9. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
10. Ettinger B, Wang SM, Leslie RS, Patel BV, Boulware MJ, et al. (2011) Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause.
11. Bretler DM, Hansen PR, Abildstrom SZ, Jorgensen CH, Sorensen R, et al. (2011) Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol 71: 105-115.
12. Shinmura K, Nagai M, Tamaki K, Bolli R, (2008) Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation. Cardiovasc Res 79: 387-394.
13. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, et al. (2003) 17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol 41: 2084-2092.
14. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP, (2003) Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 284: H1560-1569.
15. Smith PJ, Ornatsky O, Stewart DJ, Picard P, Dawood F, et al. (2000) Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation 102: 2983-2989.
16. Iwakura A, Shastry S, Luedemann C, Hamada H, Kawamoto A, et al. (2006) Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of matrix metalloproteinase-9. Circulation 113: 1605-1614.
17. Aronson D, Mutlak D, Bahouth F, Bishara R, Hammerman H, et al. (2011) Restrictive left ventricular filling pattern and risk of new-onset atrial fibrillation after acute myocardial infarction. Am J Cardiol 107: 1738-1743.
18. Jons C, Joergensen RM, Hassager C, Gang UJ, Dixen U,et al. (2010) Diastolic dysfunction predicts new-onset atrial fibrillation and cardiovascular events in patients with acute myocardial infarction and depressed left ventricular systolic function: a CARISMA substudy. Eur J Echocardiogr 11: 602-607.
19. Gaist D, Sorensen HT, Hallas J, (1997) The Danish prescription registries. Dan Med Bull 44: 445-448.
20. NOMESCO website. Available: http://www.nomesco-da.nom-nos.dk/filer/publikationer/NCSP%201_15.pdf. Accessed 2012 March 21.
21. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M, (2003) The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56: 124-130.
22. Olesen JB, Hansen PR, Abildstrom SZ, Andersson C, Weeke P, et al. (2011) Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidemiol Drug Saf 20: 146-153.
23. Tu JV, Austin PC, Walld R, Roos L, Agras J, et al. (2001) Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 37: 992-997.
24. Vermeulen MJ, Tu JV, Schull MJ, (2007) ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions. J Clin Epidemiol 60: 971-974.
25. Kumler T, Gislason GH, Kirk V, Bay M, Nielsen OW, et al. (2008) Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 10: 658-660.
26. Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, et al. (2006) Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 27: 1153-1158.
27. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, et al. (2011) Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342: d124.
28. Ekholm O, Hesse U, Davidsen M, Kjoller M, (2009) The study design and characteristics of the Danish national health interview surveys. Scand J Public Health 37: 758-765.
29. Frost L, Andersen LV, Vestergaard P, Husted S, Mortensen LS, (2007) Trend in mortality after stroke with atrial fibrillation. Am J Med 120: 47-53.
30. Frost L, Vestergaard P, (2004) Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164: 1993-1998.
31. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M, (2005) Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 112: 1736-1742.
32. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, et al. (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271: 840-844.
33. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L, (2010) Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Calcif Tissue Int 86: 335-342.
34. Berry JD, Prineas RJ, van Horn L, Passman R, Larson J, et al. (2010) Dietary fish intake and incident atrial fibrillation (from the Women's Health Initiative). Am J Cardiol 105: 844-848.
35. Margolis DJ, Knauss J, Bilker W, (2002) Hormone replacement therapy and prevention of pressure ulcers and venous leg ulcers. Lancet 359: 675-677.
36. Macchia A, Monte S, Pellegrini F, Romero M, Ferrante D, et al. (2008) Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 64: 627-634.
37. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, et al. (2009) Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Arch Intern Med 169: 1677-1683.
38. Schmidt M, Christiansen CF, Mehnert F, Rothman KJ, Sorensen HT, (2011) Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ 343: d3450.
39. Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, et al. (2005) Effect of estrogen therapy on gallbladder disease. JAMA 293: 330-339.
40. Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, et al. (2010) Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Arch Intern Med 170: 1678-1685.
41. Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, et al. (2011) Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 103: 1469-1475.
42. Magnani JW, Moser CB, Murabito JM, Nelson KP, Fontes JD, et al. (2012) Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J 163: 729-734.
43. Karim R, Stanczyk FZ, Hodis HN, Cushman M, Lobo RA, et al. (2010) Associations between markers of inflammation and physiological and pharmacological levels of circulating sex hormones in postmenopausal women. Menopause 17: 785-790.
44. Zanger D, Yang BK, Ardans J, Waclawiw MA, Csako G, et al. (2000) Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Coll Cardiol 36: 1797-1802.
45. Boos CJ, Anderson RA, Lip GY, (2006) Is atrial fibrillation an inflammatory disorder? Eur Heart J 27: 136-149.
46. Guazzi M, Arena R, (2009) Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart 95: 102-106.
47. Mitchell GF, Vasan RS, Keyes MJ, Parise H, Wang TJ, et al. (2007) Pulse pressure and risk of new-onset atrial fibrillation. JAMA 297: 709-715.
48. Al-Khalili F, Eriksson M, Landgren BM, Schenck-Gustafsson K, (1998) Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 82: 215-218.
49. Lokkegaard EL, Johnsen SP, Heitmann BL, Stahlberg C, Pedersen AT, et al. (2004) The validity of self-reported use of hormone replacement therapy among Danish nurses. Acta Obstet Gynecol Scand 83: 476-481.
50. Gorodeski EZ, (2010) Are hot flashes linked to cardiovascular risk? It is too early to tell. Menopause 17: 443-444.